Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Jazz Pharmaceuticals PLC has received an average recommendation of "Moderate Buy" from fourteen analysts; one has rated it a hold while thirteen have issued a buy recommendation.
• The average twelve-month price target for Jazz Pharmaceuticals stock is $181.43, though several brokerages have recently adjusted their target prices downward.
• Jazz Pharmaceuticals reported a loss of ($8.25) EPS for its last quarter, missing analysts' expectations, despite achieving a revenue of $1.05 billion, which matched estimates.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fifteen analysts that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $181.4286.

Several equities analysts have issued reports on the company. Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Zacks Research raised Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday. Robert W. Baird decreased their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price target for the company. Finally, Piper Sandler restated an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the sale, the chief executive officer owned 436,973 shares of the company's stock, valued at approximately $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Teacher Retirement System of Texas raised its holdings in Jazz Pharmaceuticals by 0.6% during the second quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company's stock worth $1,651,000 after purchasing an additional 90 shares in the last quarter. Versant Capital Management Inc raised its holdings in Jazz Pharmaceuticals by 9.4% during the first quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock worth $131,000 after purchasing an additional 91 shares in the last quarter. Kendall Capital Management raised its holdings in Jazz Pharmaceuticals by 1.2% during the first quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock worth $989,000 after purchasing an additional 95 shares in the last quarter. Quarry LP raised its holdings in Jazz Pharmaceuticals by 6.3% during the fourth quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock worth $209,000 after purchasing an additional 100 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its holdings in Jazz Pharmaceuticals by 0.6% during the first quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company's stock worth $2,098,000 after purchasing an additional 100 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded up $1.0470 during trading on Friday, hitting $118.7170. The company had a trading volume of 400,660 shares, compared to its average volume of 958,700. The firm has a market cap of $7.20 billion, a PE ratio of -17.64, a price-to-earnings-growth ratio of 7.42 and a beta of 0.34. Jazz Pharmaceuticals has a 1-year low of $95.49 and a 1-year high of $148.06. The firm has a 50-day moving average price of $111.94 and a 200-day moving average price of $117.12. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business's revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the firm earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, analysts expect that Jazz Pharmaceuticals will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.